A Phase II Trial of Radiation Therapy With Concurrent Paclitaxel Chemotherapy in High-Risk Endometrial Cancer Patients After Operation.
Postoperative radiotherapy (RT) is the most used adjuvant treatment in high risk endometrial
cancer (HREC), and it appears to reduce the incidence of pelvic relapses but doesn't seem to
improve survival. Paclitaxel (P) has shown in vitro and clinical activity against
endometrial cancer, and it is also a potent radiosensitizer by blocking dividing cells in
G2/M phase. This study is to evaluate the efficacy and safety of a treatment with
concomitant weekly chemotherapy with paclitaxel and RT in high risk advanced endometrial
cancer.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Two year progression free survival
Jae-Hoon Kim, Professor
Study Chair
Yong-Dong Severance Hospital
Korea: Food and Drug Administration
KGOG2001
NCT00373620
January 2006
Name | Location |
---|